Introduction
Natural retinoids are signaling molecules with important roles in growth, differentiation, and apoptosis of a variety of normal adult and embryonic tissues (De Luca, 1991) and also have potent antiproliferative effects on many malignant cell types and chemopreventive properties that, for as yet unknown reasons, do not depend upon induction of terminal differentiation (Smith et al., 1992; Gudas, 1994; Zusi et al., 2002) . They activate gene transcription via nuclear retinoic-acid receptors (RARs) and retinoid-X receptors (RXRs). RARs and RXRs are encoded by three distinct genes (a, b, and g) and efficiently bind as either RXR-RAR heterodimers or RXR homodimers to cognate response element (Chambon, 1996; Chen et al., 1996) . All-trans-RA (ATRA) is a high-affinity natural ligand only for RARs, whereas its stereoisomer, 9-cis-RA, is a high-affinity natural ligand for both RARs and RXRs (Mangelsdorf et al., 1995; Chambon, 1996; Chen et al., 1996) RXR/RAR heterodimers bind to RA response elements (RARE) and act as ligand-inducible transcription-regulatory factors in the presence of ATRA or 9-cis-RA. RXR can homodimerize or heterodimerize with other members of the nuclear receptor superfamily leading to cross-talk between several signaling pathways (Mangelsdorf et al., 1995) .
Biological responses to retinoids are currently used therapeutically in various human cancers including leukemia, skin cancer, cervical cancer, and neuroblastoma (Amos and Lotan, 1990) . Among myeloid leukemias, acute promyelocytic leukemia (APL) was found to be specifically sensitive to ATRA that induces remission of APL patients by stimulating the differentiation of the leukemic cells. Although almost all patients respond to this ATRA therapy, undesirable systemic side effects are frequently observed (called 'ATRA syndrome') and resistances to this agent often develop (Fenaux et al., 2001; Gallagher, 2002) . For these reasons, selective compounds derived from the natural ligands have been developed that exhibit significantly greater specificity for the various isoforms of the RARs and RXRs compared to the natural ligands (Lehmann et al., 1992; Chen et al., 1996; Sun et al., 2000) . Using this therapeutical approach based on the distinct retinoid receptor equipment of cells, one can expect a specific targeting of tumor cells and the induction of distinct antitumor biological responses.
Human telomerase, a ribonucleoprotein that catalyses the synthesis and extension of telomeric DNA (Greider and Blackburn, 1985; Morin, 1989) , usually inactive in most normal somatic cells, is widely activated in cancer cells, strongly indicating its key role during tumorigenesis (Meyerson et al., 1997; Weinberg, 1998; Hahn et al., 1999) . Therefore, finding compounds that can specifically inhibit telomerase activity could thus be of great therapeutic value in malignant disease. Human telomerase is composed of at least two essential components, a template RNA component (hTR; human Telomerase RNA) and a telomerase reverse transcriptase (hTERT), which is the catalytic subunit (Feng et al., 1995; Kilian et al., 1997; Meyerson et al., 1997) . The expression of hTERT is closely associated with telomerase activity (Weinrich et al., 1997) . In the last few years, numerous anticancer strategies targeting telomerase components or telomeric DNA have been proposed (Helder et al., 2002; Mergny et al., 2002) . However, only few compounds have been described as inhibiting the expression of hTERT, certainly because molecular mechanisms that negatively control hTERT mRNA are not yet fully understood (Xu et al., 2000; Chou et al., 2001; Pendino et al., 2001) . We have recently shown that in a maturation-resistant APL cell line, NB4-LR1, the pharmacological concentration of ATRA exhibits antiproliferative properties, independent of terminal maturation, through downregulation of telomerase leading to telomere shortening and cell death (Pendino et al., 2001) .
To further gain insights into the mechanisms by which ATRA represses hTERT expression, we examined in this study the effects of receptor-selective retinoids, alone or in combination with two different types of maturation-resistant APL cells and showed that telomerase repression was obtained only when both RARa and RXR agonists were used in association. These results indicate first, the requirement of both receptors in the regulation of hTERT expression, and second, that this kind of cotreatment could be of great clinical interest for an efficient targeting of telomerase with fewer side effects.
Results

ATRA induces a dose-dependent inhibition of telomerase activity and proliferation
A new pathway for hTERT regulation, previously identified in the RAR-responsive, maturation-resistant NB4-LR1 cell line (Pendino et al., 2001 ) (derived from human APL cells with the disease-generating fused promyelocytic leukemia (PML)-RAR gene), leads to a gradual downregulation of telomerase activity (TA) developing slowly during ATRA treatment at pharmacological concentration (1 mM), then to telomere shortening and subsequently to cell death. In order to investigate whether this maturation-independent response can be obtained at lower doses of ATRA, a dose-response experiment was performed (Figure 1 ). We observed a reproducible growth arrest followed by cell death (data not shown) within 2-3 weeks only at therapeutic ATRA concentrations of 0.5 and 1.0 mM. Even though the number of population doublings is higher for cells treated with ATRA 0.5 mM compared to cells treated with ATRA 1 mM, most of the cells underwent cell death within approximately the same time in both cases. It may indicate that some effects of ATRA on cell growth occurred in a telomeraseindependent mechanism. The use of lower ATRA concentrations (o200 nM) was insufficient to induce growth arrest and cell death. Checking for TA at day 10 (a moment when the cells were still in the exponential growth phase and TA stabilized, Pendino et al., 2001) , it was observed that the ATRA dose-response curve of TA inhibition exhibited a biphasic pattern. This observation suggests that an ATRA-signaling threshold (estimated between 0.2 and 0.5 mM) is necessary to reach a telomerase inhibition threshold (estimated at 60%) to induce growth arrest and then cell death (see below).
RARs-specific agonists alone or in combination are not sufficient to downregulate TA efficiently Pondering why TA downregulation by the natural, RAR pan-agonist ATRA exhibits this pattern of Targeting hTERT expression by receptor-specific retinoids F Pendino et al dose-response, we wondered whether selective agonists for RAR subtypes would be specifically involved in hTERT downregulation. To explore this possibility, the effects of long-term NB4-LR1 cells treatment with pure RARa-(Am580), RARb-(CD2314) or RARg(CD666) agonists, known to be receptor specific at appropriate concentrations (0.2 mM) (Sun et al., 2000) , were compared to that obtained with 1 mM ATRA, in terms of cell proliferation and TA (Figure 2a) . On day 17, most of the 1 mM ATRA-treated cells were dead (data not shown) compared to continuous growth in the presence of RARa, RARb or RARg agonists alone (0.2 mM) or in combination, or RXR agonist alone (0.5 mM). Even at high concentrations (1.0 mM, data not shown), neither the RARb nor the RARg agonist affected the level of TA, but the RARa-specific agonist (0.2 mM) was able to inhibit TA (30%) weakly but reproducibly, and slow population doubling moderately. However, of note, and as expected from the previous results (Figure 1 ), this inhibition was not sufficient to induce cell death, even at the highest dose tested (1 mM) and after more than 1 month of treatment (data not shown). Notably, adding RARb and RARg agonists at selective concentrations (0.2 mM) to NB4-LR1 cell cultures did not enhance the weak RARa-specific TA inhibition (compare lanes 3 and 6). This observation suggests that neither the RARb nor -g isotype is involved in telomerase downregulation in this cell line.
Combination of RARa and RXR-specific agonists induces telomerase downregulation, telomere shortening and cell death
Given that (1) the RARa agonist alone does not fully downregulate telomerase, (2) neither RAR-b nor -g agonist could complement the RARa-dependent activity, and (3) the ATRA is a potent regulator of TA, we hypothesized that 9-cis-RA, a high-affinity natural ligand for both RARs and RXR, generated by ATRA isomerization (Urbach and Rando, 1994; Van heusden Interestingly, even though these two agonists on their own induced a significant decrease of hTERT mRNA (83 and 72% for RARa and RXR agonist, respectively), this repression was not sufficient to result in an effective inhibition of telomerase (30 and 15%, respectively). This observation indicates a necessary threshold in the downregulation of hTERT mRNA in order to obtain a sufficient inhibition of telomerase (i.e. below 60% of the control activity) leading to cell death. This can Targeting hTERT expression by receptor-specific retinoids F Pendino et al partially be explained by the long half-life of the hTERT protein (Xu et al., 1996) .
Pertinently, the combined agonist experiments (Figure 3a) clearly demonstrated that at least 60% inhibition of TA was reached with all combinations of both agonists (from 12.5 to 200 nM of RARa-(Am580) and 62.5 to 500 nM of RXR-(SR11237)) suggesting, as discussed above, that these combinations will be effective in inducing cell death by a telomerasedependent pathway. This was checked for the combination of agonists using 125 nM RXR and 12.5 nM RARa that induced 70% inhibition of TA and led to growth arrest and cell death (Figure 3b ). This synergistic effect is not specific to the RXR agonist used, as it was also observed with another RXR agonist, the CD3640 (data not shown).
Both NB4-LR1/hTERT-GFP and NB4-LR1
SFD are resistant to long-term treatment with the combination of RARa-(Am580) and RXR-(SR11237) agonists
To confirm that cell death induced by the combination of RARa and RXR agonists results from a telomerasedependent mechanism, we investigated whether ectopic hTERT expression could rescue NB4-LR1 cells from death induction by a long-term treatment with the RARa and RXR agonist combination (Figure 4 ). This retrovirally infected NB4-LR1/hTERT-GFP subline has already been described (Pendino et al., 2001 (Pendino et al., , 2002 NB4-LR1 and NB4-LR1/GFP cells treated with either ATRA or RARa and RXR agonist combination demonstrated a period of reduced growth (Figure 4a ) and after 18 days underwent massive cell death (Figure 4b ) due to shortening of the telomere length (Figure 4c ). In contrast, NB4-LRl/hTERT-GFP cells continued to proliferate without any significant shortening of telomere length. These findings demonstrate that ectopic hTERT expression was sufficient to prevent telomere shortening and cell death in this setting and that telomerase downregulation and subsequent telomere shortening, induced by long-term treatment with RARa and RXR agonists, are the main causes of cell death.
Pertinently, the new ATRA-selected variant NB4-LR1 SFD , previously isolated for its resistance to the death induction by long-term ATRA treatment, because of its defective pathway for ATRA long-term downregulation of telomerase activity (Pendino et al., 2002) , was also resistant to the agonists combination (Figure 4 ).
Unlike ATRA, dual-signaling between RARa and RXR agonists targets telomerase activity in the maturation resistant NB4-LR2 cells It was previously shown that the NB4-LR1 cell line is an ATRA-responsive cell line for which ATRA alone failed to induce maturation, but rendered these cells competent to maturation triggering by cAMP signaling (Ruchaud et al., 1994) . No such cooperation exists in the NB4-LR2 cell line because of a mutation of Gln411 to an in-phase stop codon in the ligand-binding domain of PML-RARa (Duprez et al., 1992 (Duprez et al., , 2000 Ruchaud et al., 1994) . Furthermore, it was previously shown (Pendino et al., 2001 ) that in contrast to what was observed in the NB4-LR1 cells, TA remained stable after a small decrease in ATRA long-term treatment of the NB4-LR2 cells and proliferation continued, suggesting that this decrease was not sufficient to induce death in these resistant cells. To assess whether the combined effect of RARa and RXR agonists on telomerase expression is a specific feature of the ATRA-responsive maturation-resistant NB4-LR1 cells, or whether this dual-signaling can also target telomerase in the maturation-resistant NB4-LR2 cells, a similar study was performed using the retrovirally transduced maturation-resistant NB4-LR2/GFP and NB4-LRl/ hTERT-GFP and both the RARa-(Am580) and RXR-(CD3640) agonists.
Both cell lines were exposed to the long-term treatment with ATRA (1 mM) or either RARa-(Am580, 0.2 mM) or RXR-(CD3640, 0.5 mM) alone or in combination and compared in terms of cell proliferation, hTERT expression and TA ( Figure 5 ). Quantitative RT-PCR analysis (Figure 5a , upper) showed that ATRA alone was able to downregulate hTERT mRNA in NB4-LR2/ GFP cells, but this decrease (74% of the untreated cells) remains lower than that observed in the NB4-LR1 cells (94% of the untreated cells) treated in the same conditions ( Figure 2b , lane 2). As already reported for the parental NB4-LR2 cells (Pendino et al., 2001) , this repression was not sufficient to induce a significant decrease in TA leading to growth arrest and cell death (Figure 5a , medium, and b, upper). Similarly, a downregulation of hTERT mRNA was observed in NB4-LR2/GFP cells treated with the RARa-(Am580) or the RXR-(CD3640) agonist alone (45 and 75%, respectively). However, this effect resulted in both cases in less than 20% TA inhibition. As expected from the above results, such a weak inhibition of TA had no significant effect on proliferation of the treated NB4-LR2/ GFP cells (Figure 5b, bottom) . Interestingly, the combination of the RARa agonist with the RXR agonist synergistically downregulated hTERT mRNA in NB4-LR2/GFP cells (90%) leading to a higher decrease of TA (61%) than that observed with ATRA alone (19%). Furthermore, and in contrast to ATRA treatment, this combination was effective in inducing telomere shortening and death of these cells (Figure 5a lower, and c). Telomerase constitutively overexpressed by means of hTERT retroviral transfer into this cell line abolished this synergistic response, indicating that this death is the result of a telomerase-dependent mechanism. These results demonstrate that a synergistic retinoid signaling targeting of telomerase can also develop in different kinds of ATRA maturation-resistant NB4 cells.
Discussion
ATRA-based differentiation therapy leads to complete remission in most APL patients by inducing the
Targeting hTERT expression by receptor-specific retinoids F Pendino et al differentiation of immature promyelocytic blast cells into mature granulocytes, which subsequently undergo apoptosis (Gallagher, 2002) .
Recently, we have shown that telomerase can be repressed by pharmacological concentration of ATRA (1 mM) independently of terminal maturation during long-term ATRA treatment of the maturation-resistant promyelocytic leukemia cell line, NB4-LR1 (Pendino et al., 2001) . In the present paper, dose-response investigations demonstrate that (1) growth arrest and cell death can be achieved only when more than 60% of telomerase inhibition is reached, (2) such an inhibition requires a pharmacological concentration of ATRA (0.5-1 mM). Therefore, despite this high in vitro efficacy of ATRA to downregulate telomerase (Pendino et al., 2001 (Pendino et al., , 2002 , any validation of an ATRA-based antitelomerase therapy using this high concentration of ATRA can be questioned. Furthermore, the long-term ATRA use at pharmacological concentration is hampered by undesirable systemic side effects, including RA syndrome and selection of ATRA-resistant tumor cells.
Over the last few years, new retinoids preferentially binding to individual RARs or RXRs, have been synthesized for therapeutical use (Delescluse et al., 1991; Lehmann et al., 1991; Bernard et al., 1992) and clinical benefits are now under evaluation both in vitro on cell lines and in vivo on animals models. In this context, we wondered whether the activation of a particular nuclear receptor might explain why such a high concentration of ATRA is needed to obtain this telomerase-dependent cell death. We show that synthetic receptor-selective agonists, RARa-(Am580) and RXR-(SR11237; CD3640), cooperate to downregulate telomerase synergistically leading to growth arrest and cell death of NB4-LR1 cells at very low concentrations of 12 and 125 nM, respectively. This effect is not specific to the NB4 maturation-resistant cell line since it is also observed in the NB4-LR2 cell line. These results demonstrate that the occupancy of the ligand-binding sites of both RXR and (PML-)RARa in a heterodimer is required to mediate the optimal telomerase downregulation consistent with cell death. This enables us to propound a reasonable explanation for the threshold of ATRA activity, that is the steady cellular production of small amounts of the natural RXR ligand (9-cis-RA) as a byproduct of ATRA by isomerization (about 7-9%) (Urbach and Rando, 1994; Van heusden et al., 1998) . Although the precise mechanisms remain to be elucidated, these results, indicating that receptor cross-talk does exist within a double-liganded heterodimeric receptor complex and is necessary for efficient hTERT Targeting hTERT expression by receptor-specific retinoids F Pendino et al regulation, are consistent with previous observations that both RAR and RXR partners of RAR-RXR heterodimers can synergistically activate transcription of RA-responsive genes (Roy et al., 1995; Germain et al., 2002) . However, more complex mechanisms, like ligand-activated RXR-RXR homodimers or cooperation between events independently induced by the (PML-)RARa-and RXR-specific ligands cannot be excluded.
These results may have clinically relevant applications for the prevention and treatment of APL. First, they show that the use of ATRA as a therapeutic agent to target telomerase could have a limiting parameter, the ligand-dependent coactivation of RXR. Second, they raise the possibility that it might be possible to lower the dose of the RARa-selective agonists and attenuate their side effects without compromising their action by combining them with RXR-selective agonists, which in human clinical trials did not manifest the side effects that are normally associated with retinoid therapy (Miller et al., 1997) . Thus, specific combination of selective-receptor synthetic retinoids may extend the therapeutic use of retinoids and provide a new therapeutic tool for anticancer treatment distinct from other telomerase-based antitumor strategies that are currently under investigation (Helder et al., 2002; Mergny et al., 2002) .
In addition to the demonstration that no antitumor benefit can be expected from hTERT downregulation by retinoids until a reduction of telomerase activity below the minimal threshold of activity required to sustain growth (below 40% in NB4-LR1 cells), this work clearly indicates that the efficacy of retinoids will depend upon the genetic status and phenotypic features of the tumor cells treated. Our comparison of two ATRA maturation-resistant APL sublines derived from the same parental tumor cell, NB4-LR1 cell (an RARa-responsive cell line depending on cAMP signaling) and NB4-LR2 (a PML-RARa mutated cell line, apparently unresponsive to ATRA), exquisitely shows that this apparent unresponsiveness to ATRA can be overcome by using appropriate pairs of RARa-and RXR-selective agonists. Indeed, the combined action of Am580 and CD3640 can efficiently overcome the strong dominant negative activity of the Gln411-mutated PML-RARa (32), which is not obtained with ATRA.
Such targeting of hTERT through a hormonal pathway by means of receptor-specific agonists could also have an impact on other cancers, not only in those known to be sensitive to the antiproliferative effects of retinoids but also in those reputed resistant to natural retinoids. Of note, preliminary investigations have shown that this targeting is also effective in A549 lung carcinoma cells and in HeLa cervical ovarian carcinoma cells (unpublished results). However, it becomes obvious from the above results that the efficacy of this therapeutical strategy will depend on the level of telomerase inhibition obtained by a given RXR/RAR agonist combination.
Altogether, these findings will encourage the development and screening of more effective synthetic receptor-specific retinoids for tumor cell type-specific treatments leading to cell death through an efficient repression of telomerase.
Materials and methods
Reagents and drugs
ATRA was purchased from Sigma (St Louis, MO, USA). Am580, CD2314, CD666, CD3640 provided by CIRDGalderma (Sophia-Antipolis, Valbonne, France) are synthetic retinoids with respective RARa, -b, -g, and RXR selectivity (Sun et al., 2000) . Dr Gronemeyer (Illkirch, France) provided the selective synthetic RXR agonist SR11237.
Cell lines and cell culture
The maturation-resistant human promyelocytic leukemia cell lines NB4-LR1 and NB4-LR2 (Lanotte et al., 1991; Duprez et al., 1992; Ruchaud et al., 1994) , the selected subline, NB4-LR1 SFD unresponsive to long-term maturation-independent regulation of telomerase (Pendino et al., 2002) , the retroviraly infected NB4-LRl/hTERT-GFP subline (Pendino et al., 2001) , and the NB4-LR2/hTERT-GFP (see below) expressing both the hTERT protein and the green fluorescent protein (GFP) reporter from the same transcript, the NB4-LR1/GFP subline and the NB4-LR2/GFP expressing only the GFP control vector, were cultured as described previously (Lanotte et al., 1991; Pendino et al., 2002) . Both NB4-LR1 SFD and NB4-LRl/ hTERT-GFP sublines escape death induced by long-term ATRA treatment (Pendino et al., 2001 (Pendino et al., , 2002 . Cell density was determined using a Coulter counter and proliferation was expressed as population doublings (PD). Cell morphology was evaluated after May-Gru¨nwald-Giemsa staining of cytocentrifuged preparations, as previously described (Duprez et al., 1992) .
Plasmids and lentiviral infections
The lentiviral plasmids were kindly constructed and provided by KA Westerman and P Leboulch (Genetix Pharmaceuticals, 840 Memorial Drive, Cambridge, MA, USA). Briefly, SSR221-hTERT plasmid was obtained by introducing hTERT cDNAs, a generous gift from R A Weinberg (Massachusetts Institute of Technology, Cambridge, MA, USA) into the control lentivirus HPV422 (EFlalpha-IRES-GFP). HEK 293T cells were transiently cotransfected with pCMVDR8.74 encapsidation plasmid and vesicular stomatitis virus (VSV) envelope-expression plasmid (pMD2G) kindly provided by L Naldini (Laboratory for Gene Transfer and Therapy IRCC, Institute for Cancer Research and Treatment, University of Torino Medical School, Torino, Italy) using exgen 500 (Euromedex, Souffelweyersheim, France). Viral supernatants were harvested and concentrated by ultracentrifugation for further NB4-LR2 cells infections, which were carried out in the presence of 4 mg of Polybrene/ml. Infected NB4-LR2 cells were sorted 2 days later by flow cytometry according to GFP fluorescence.
Telomerase activity assay
TA was measured using a modified version of the standard telomeric repeat amplification protocol (TRAP) (Kim et al., 1994) , the telomerase polymerase chain reaction (PCR) enzyme-linked immunosorbent assay (ELISA) kit (TRAPeze Elisa telomerase detection kit, Qbiogene, Illkirch, France) according to the manufacturer's instructions. In selected Targeting hTERT expression by receptor-specific retinoids F Pendino et al experiments, results obtained with treated cells were expressed as relative TA, attributing 100% activity to the control extract of the untreated parental NB4-LR1 or NB4-LR2 cells.
Telomere length analysis
Telomere length was measured using a nonradioactive chemiluminescent assay developed by Roche Diagnostics (Meylan, France), according to the manufacturer's instructions. The average telomeres lengths can be determined by comparing the signals relative to a molecular mass standard.
RT-PCR analysis of hTERT expression
The expression of hTERT mRNA was analysed by semiquantitative RT-PCR amplification. Total cellular RNA was extracted from samples using TRIzol reagent (Invitrogen, Cergy Pontoise, France). RNA yields and purity were determined spectrophotometrically at 260-280 nM and by visualization after electrophoresis of ribosomal bands (28S) on 1% agarose gels stained with ethidium bromide (0.5 mg/ml).
RT-PCR was carried out with 1 mg of total mRNA by using random primers and the 'Reverse Transcription System' (Promega, Lyon, France) following the manufacturer's instructions. hTERT cDNA amplification was performed as previously described (Pendino et al., 2001 ) using TERT-2164S and TERT-2620A primers. Human telomerase RNA (hTR) cDNA was amplified with primers F3b and R3c. Glyceraldhehyde-3-phosphate dehydrogenase (GAPDH) mRNA, used as an external standard (RNA extraction, RT efficiency and product loading), was amplified from the same cDNA reaction mixture, using the primers K136 and K137 as previously described (Pendino et al., 2001) . Amplified products were electrophoresed on a 2% high-resolution agarose gel (Metaphore Agarose, Tebu, Le Perray en Yvelines, France) and stained with ethidium bromide (0.5 mg/ml), visualized under UV light and photographed. Full-length hTERT mRNA expression was quantified by fluorescence real-time RT-PCR using the LightCycler s technology and the LightCycler TeloTAGGG hTERT kit From Roche Diagnostics (Meylan, France) according to the manufacturer's instructions. The hTERT level was normalized to the expression of the housekeeping gene phosphobilinogen deaminase (PBGD).
